Vaccination News

Northeastern cities, including New York and Washington, D.C., have seen a surge in COVID-19 cases, but increased immunization, low hospitalization rates and a growing armamentarium against infection may serve to temper calls for alarm.

The Coalition for Epidemic Preparedness Innovations, or CEPI, launched a multi-billion dollar plan to accelerate the development and production of vaccines during the next pandemic, with a goal of making them available in just 100 days.

Vaccinated people who were subsequently infected with SARS-CoV-2 experienced a shorter duration of symptoms if they were infected with the omicron variant vs. the delta variant, mobile-app based data showed.

As of April 1, about 80 million cases of SARS-CoV-2 infection have been reported in the U.S., according to the CDC. Among them are rising incidences of long COVID, a condition that is still not completely understood by clinicians.

There were no significant associations between COVID-19 vaccination and adverse pregnancy outcomes in a cohort of pregnant women in Sweden and Norway, findings published in JAMA showed.

Last week, the FDA authorized a second COVID-19 booster dose for people aged 50 years or older and certain immunocompromised individuals.

People aged 50 years or older with COVID-19 had a 15% increased risk for developing herpes zoster, according to the results of a large retrospective cohort study.

In this video, Andrew Pinto, MD, CCFP, FRCPC, MSc, discusses best practices for planning and implementing successful COVID-19 vaccination clinics in Canada and the United States.

In the United States, the omicron subvariant BA.2 accounted for 35% of SARS-CoV-2 infections in the week ending March 19, according to the CDC.

The FDA on Tuesday authorized a second booster dose of COVID-19 vaccine for people aged 50 years or older and certain immunocompromised patients, citing evidence that it improves protection against severe disease.